News | October 16, 2023
ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Marks the World Head & Neck Cancer Day at the OCTF Conference
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Subscribe To Our Newsletter & Stay Updated
